Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 7/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.41 |
| ▸ | MAT2A | P31153 | 8/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20736835 | 0.88 | MAT2A (0.40) | CYP1A1CYP1A2MAT2ASIRT2SIRT1 | |
| SCHEMBL10331669 | 0.88 | KDM4E (0.41) | CYP1A1CYP1A2CYP1B1SIRT2SIRT1 | |
| SCHEMBL16067706 | 0.87 | KDM4E (0.42) | CYP1A1CYP1A2CYP1B1SIRT2SIRT1 | |
| SCHEMBL20737606 | 0.87 | AHR (0.49) | MAT2APRMT5AHRMAPK8MAPK9 | |
| SCHEMBL19830461 | 0.87 | CYP1A1 (0.39) | CYP1A1CYP1A2CYP1B1SIRT2SIRT1 | |
| SCHEMBL16067697 | 0.86 | KDM4E (0.39) | CYP1A1CYP1A2CYP1B1SIRT2SIRT1 | |
| SCHEMBL20737604 | 0.86 | MAT2A (0.37) | MAT2APRMT5AHRMAPK8MAPK9 | |
| SCHEMBL20737621 | 0.86 | MAT2A (0.41) | CYP1A2MAT2APRMT5AHRMAPK8 | |
| SCHEMBL26846185 | 0.86 | KDM4E (0.41) | CYP1A1CYP1A2CYP1B1SIRT2SIRT1 | |
| SCHEMBL16067535 | 0.85 | KDM4E (0.38) | CYP1A1CYP1A2CYP1B1SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11081649-B2 | Compound for organic electronic element, organic electronic element using same, and electronic device thereof | DUK SAN NEOLUX CO., LTD. (KR) | 2021-08-03 | — | — | US | disclosed |
| US-20190051840-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING SAME, AND ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11081649-B2 | Compound for organic electronic element, organic electronic element using same, and electronic device thereof | PIEZO1, OR51E2, OR10J3 | CYP1A1 429/4885CYP1A2 826/4885CYP1B1 989/4885 |
| US-20190051840-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING SAME, AND ELECTRONIC DEVICE THEREOF | PIEZO1, OR51E2, OR10J3 | CYP1A1 429/4885CYP1A2 826/4885CYP1B1 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.